MorphoSys, Xencor complete patient enrollment in Phase I CLL trial
MOR208 (formerly XmAb5574) is a potent anti-CD19 antibody with a proprietary modification to the Fc portion, that is being developed to treat B-cell malignancies. The open-label, multi-dose, single-arm,